12:00 AM
Jul 09, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Iluvien medidur: Phase I/II started

pSivida said investigators began a U.S. Phase I/II trial to evaluate Medidur in posterior uveitis patients. Alimera Sciences Inc. (NASDAQ:ALIM, Alpharetta, Ga.)...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >